Cellceutix files pre-IND submission with FDA on new psoriasis drug - Pharmaceutical Business Review

Cellceutix files pre-IND submission with FDA connected new psoriasis drug medicine Business Review Biopharmaceutical establishment Cellceutix has filed type A pre-IND submission with the US Food and Drug Administration (FDA) on Prurisol (also termed KM-133), the company's drug in development as a novel attention for psoriasis . The company's submission provides ... and more » Link To Article